Kwanghee Kim

Kwanghee Kim

Auto-generated profile, based on publicly available information

Kwanghee Kim

Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2020 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
KHKatja Haedicke
Katja Haedicke
LALilach Agemy
Lilach Agemy
MOMurad Omar
Murad Omar
ABAndrei Berezhnoi
Andrei Berezhnoi
SRSheryl Roberts
Sheryl Roberts
JGJan Grimm
Jan Grimm

24 April 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
KKKwanghee Kim
Kwanghee Kim
WHWenhuo Hu
Wenhuo Hu
FAFrançois Audenet
François Audenet
NANima Almassi
Nima Almassi
AHAphrothiti J. Hanrahan
Aphrothiti J. Hanrahan
JCJonathan Coleman
Jonathan Coleman
Treatment paradigms for patients with upper tract urothelial carcinoma (UTUC) are typically extrapolated from studies of bladder cancer despite their distinct clinical and molecular characteristics. The advancement of UTUC research is hampered by the lack of disease-specific models. Here, we report the establishment of patient derived xenograft (PDX) and cell line models that reflect the genomic and biological heterogeneity of the human disease. Models demonstrate high genomic concordance with the corresponding patient tumors, with invasive tumors more likely to successfully engraft. Treatment of PDX models with chemotherapy recapitulates responses observed in patients. Analysis of a HER2 S310F-mutant PDX suggests that an antibody drug conjugate targeting HER2 would have superior efficacy versus selective HER2 kinase inhibitors. In sum, the biological and phenotypic concordance between patient and PDXs suggest that these models could facilitate studies of intrinsic and acquired resistance and the development of personalized medicine strategies for UTUC patients.

2 November 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
JWJoshua I. Warrick
Joshua I. Warrick
WHWenhuo Hu
Wenhuo Hu
HYHironobu Yamashita
Hironobu Yamashita
VWVonn Walter
Vonn Walter
LSLauren Shuman
Lauren Shuman
HAHikmat A. Al-Ahmadie
Hikmat A. Al-Ahmadie
Cancers arising from the bladder urothelium often exhibit lineage plasticity with regions of urothelial carcinoma adjacent to or admixed with regions of divergent histomorphology, most commonly squamous differentiation. To define the biologic basis for and clinical significance of this morphologic heterogeneity, here we perform integrated genomic analyses of mixed histology bladder cancers with separable regions of urothelial and squamous differentiation. We find that squamous differentiation is a marker of intratumoral genomic and immunologic heterogeneity in patients with bladder cancer and a biomarker of intrinsic immunotherapy resistance. Phylogenetic analysis confirms that in all cases the urothelial and squamous regions are derived from a common shared precursor. Despite the presence of marked genomic heterogeneity between co-existent urothelial and squamous differentiated regions, no recurrent genomic alteration exclusive to the urothelial or squamous morphologies is identified. Rather, lineage plasticity in bladder cancers with squamous differentiation is associated with loss of expression of FOXA1, GATA3, and PPARG, transcription factors critical for maintenance of urothelial cell identity. Of clinical significance, lineage plasticity and PD-L1 expression is coordinately dysregulated via FOXA1, with patients exhibiting morphologic heterogeneity pre-treatment significantly less likely to respond to immune checkpoint inhibitors.

5 July 2023 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
SMSteven B. Maron
Steven B. Maron
WCWalid Chatila
Walid Chatila
HWHenry Walch
Henry Walch
JCJoanne F. Chou
Joanne F. Chou
NCNicholas Ceglia
Nicholas Ceglia
YJYelena Y. Janjigian
Yelena Y. Janjigian
Purpose: We report updated clinical outcomes from a phase II study of pembrolizumab, trastuzumab, and chemotherapy (PTC) in metastatic esophagogastric cancer in conjunction with outcomes from an independent Memorial Sloan Kettering (MSK) cohort. Patients and Methods: The significance of pretreatment 89Zr-trastuzumab PET, plasma circulating tumor DNA (ctDNA) dynamics, and tumor HER2 expression and whole exome sequencing was evaluated to identify prognostic biomarkers and mechanisms of resistance in patients treated on-protocol with PTC. Additional prognostic features were evaluated using a multivariable Cox regression model of trastuzumab-treated MSK patients (n = 226). Single-cell RNA sequencing (scRNA-seq) data from MSK and Samsung were evaluated for mechanisms of therapy resistance. Results: 89Zr-trastuzumab PET, scRNA-seq, and serial ctDNA with CT imaging identified how pre-treatment intrapatient genomic heterogeneity contributes to inferior progression-free survival (PFS). We demonstrated that the presence of intensely avid lesions by 89Zr-trastuzumab PET declines in tumor-matched ctDNA by 3 weeks, and clearance of tumor-matched ctDNA by 9 weeks were minimally invasive biomarkers of durable PFS. Paired pre- and on-treatment scRNA-seq identified rapid clearance of HER2-expressing tumor clones with expansion of clones expressing a transcriptional resistance program, which was associated with MT1H, MT1E, MT2A, and MSMB expression. Among trastuzumab-treated patients at MSK, ERBB2 amplification was associated with improved PFS, while alterations in MYC and CDKN2A/B were associated with inferior PFS. Conclusions: These findings highlight the clinical relevance of identifying baseline intrapatient heterogeneity and serial ctDNA monitoring of HER2-positive esophagogastric cancer patients to identify early evidence of treatment resistance, which could guide proactive therapy escalation or deescalation.

23 December 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
JWJoshua I. Warrick
Joshua I. Warrick
WHWenhuo Hu
Wenhuo Hu
HYHironobu Yamashita
Hironobu Yamashita
VWVonn Walter
Vonn Walter
LSLauren Shuman
Lauren Shuman
HAHikmat A. Al-Ahmadie
Hikmat A. Al-Ahmadie

20 December 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
ZCZiyu Chen
Ziyu Chen
XTXinran Tang
Xinran Tang
JEJordan E. Eichholz
Jordan E. Eichholz
AMAndrew William McPherson
Andrew William McPherson
JTJasmine Thomas
Jasmine Thomas
DSDavid B. Solit
David B. Solit
HER2, encoded by the ERBB2 gene, is a receptor tyrosine kinase frequently activated in human cancers via gene amplification, mutation, and/or protein overexpression. In an analysis of 42,415 prospectively analyzed solid tumors, we show that 14.5% of urothelial cancers (n = 295/2,035) have oncogenic or likely oncogenic ERBB2 alterations (6.7% ERBB2 mutation, 6.3% amplification of wildtype ERBB2 , and 1.5% concurrent mutation and amplification). Discordance of ERBB2 mutational status between primary and metastatic disease sites is common in patients with urothelial cancer as is discordance of ERBB2 mutational status between patient-derived organoid/xenograft models and the tumors from which they were derived. In patient-derived urothelial cancer models, the HER2-targeted antibody-drug conjugate (ADC) trastuzumab deruxtecan is significantly more effective than the HER kinase inhibitor neratinib. In a real-world cohort of patients with urothelial cancer treated with trastuzumab deruxtecan, co-mutation and amplification of ERBB2 is associated with exceptional clinical response. Our data support expanded clinical trials of HER2-targeted ADCs for urothelial cancers with low HER2 expression, the clinical testing of HER2 ADCs with alternative cytotoxic payloads, and the development of functional precision oncology platforms capable of assessing payload sensitivity pre-treatment as a guide to individualized therapy selection.